EPI和THP预防浅表性膀胱癌术后复发的疗效及对患者生存质量的影响
|
摘要
目的探讨应用EPI和THP预防浅表性膀胱癌术后复发的疗效及对患者生存质量的影响。方法选取行浅表性膀胱癌术的110例SBC患者展开临床分析,随机分成研究组(THP)与对照组(EPI)。研究组使用吡柔比星实施术后膀胱内灌注治疗,对照组使用表柔比星实施术后膀胱内灌注治疗。对2组患者均随访12月,通过观察2组患者经治疗后的复发率来判断2种药物的疗效,并对比2组的不良反应、生活质量。结果研究组经治疗后复发率为10.9%,对照组经治疗后复发率为16.4%(P>0.05);研究组经治疗后不良反应发生率为54.5%,对照组经治疗后不良反应发生率为47.3%(P>0.05);2组生活质量评分无统计学差异。结论 EPI和THP的药理作用相似,均可以有效地预防行浅表性膀胱癌术后复发的结局,且不良反应发生率也相当,均具有临床推广的价值。
Objective To investigate the efficacy of EPI and THP in the prevention of postoperative recurrence of superficial bladder cancer and its influence on the quality of life of patients with superficial bladder cancer. Methods 110 patients with superficial bladder cancer who had been treated with SBC surgery were randomly divided into the study group( THP) and the control group( EPI). The study group treated with intravesical instillation of pirarubicin. The control group treated with epirubicin after intravesical instillation. 2 groups of patients were followed up for 12 months. The efficacy of the 2 drugs was evaluated by observing the recurrence rate of the 2 groups after treatment,and the adverse reactions and quality of life in the 2 groups were compared. Results The study group after treatment,the recurrence rate was 10. 9%,the control group after treatment,the recurrence rate was 16. 4%( P > 0. 05); the study group after treatment,the incidence of adverse reaction was 54. 5%,the control group after treatment,the incidence of adverse reaction was 47. 3%( P > 0. 05); quality of life of the 2 groups had no statistical difference. Conclusion The pharmacological effects of EPI and THP are similar,which can effectively prevent the recurrence of superficial bladder cancer after operation,and the incidence of adverse reactions is the same. It is worthy of clinical promotion.
Objective To investigate the efficacy of EPI and THP in the prevention of postoperative recurrence of superficial bladder cancer and its influence on the quality of life of patients with superficial bladder cancer. Methods 110 patients with superficial bladder cancer who had been treated with SBC surgery were randomly divided into the study group( THP) and the control group( EPI). The study group treated with intravesical instillation of pirarubicin. The control group treated with epirubicin after intravesical instillation. 2 groups of patients were followed up for 12 months. The efficacy of the 2 drugs was evaluated by observing the recurrence rate of the 2 groups after treatment,and the adverse reactions and quality of life in the 2 groups were compared. Results The study group after treatment,the recurrence rate was 10. 9%,the control group after treatment,the recurrence rate was 16. 4%( P > 0. 05); the study group after treatment,the incidence of adverse reaction was 54. 5%,the control group after treatment,the incidence of adverse reaction was 47. 3%( P > 0. 05); quality of life of the 2 groups had no statistical difference. Conclusion The pharmacological effects of EPI and THP are similar,which can effectively prevent the recurrence of superficial bladder cancer after operation,and the incidence of adverse reactions is the same. It is worthy of clinical promotion.
引文
[1]朱圣亮,杨芳.丝裂霉素C或吡柔比星膀胱灌注预防浅表性膀胱癌术后复发的疗效比较[J].蚌埠医学院学报,2013,11(6):729-731.
[2]林豪胜,吴保忠,杨帝宽.吡柔比星与丝裂霉素C膀胱内灌注预防浅表性膀胱癌术后复发的疗效比较[J].中国实用医药,2013,27(16):59-60.
[3]杨家荣,刘伟,刘波.膀胱癌患者尿液中BLCA-4表达的临床意义[J].实用癌症杂志,2015,30(2):168-170.
[4]Donaldson SB,Bonington SC,Kershaw LE,et al.Kershaw.Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect[J].Eur J Radiol,2013,82(12):634-638.
[5]罗建斌.经尿道膀胱肿瘤电切术联合化疗治疗T2a及T2b期膀胱癌的临床观察[J].实用癌症杂志,2015,4(9):1317-1319.
[6]王文俊,宣强.经尿道电切术和开放手术治疗早期膀胱癌的手术效果及预后比较[J].实用癌症杂志,2015,30(2):276-278.
[7]Zhang N,Jiang G,Liu X,et al.Prediction of bacillus calmette-guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies[J].Biomed Res Int,2016,2(6):634-638.
[8]Han E,Jang SY,Kim G,et al.Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes[J].Medicine,2016,95(6):634-638.
[9]Carina Bernardo,Céu Costa,Carlos Palmeira.What we have learned from urinary bladder cancer models[J].Journal of Cancer Metastasis and Treatment,2016,2(2):59.
[10]Di Mattina AJ,Fazelat A,Santaro A.Exudative retinal detachment reveals metastatic bladder cancer[J].Optom Vis Sci,2016,93(5):549-554.
[11]许丹,张丽东,徐彤,等.膀胱癌术后吡柔比星膀胱内灌注治疗的方法与护理对策[J].中国医药指南,2016,14(27):233-234.
[12]谢剑云,张新安,陈伟东.参斛汤联合吡柔比星膀胱灌注对膀胱癌术后患者不良反应、生存质量的影响[J].河南中医,2015,35(12):3042-3044.
[13]曹广辉,张治国,邱功阔.膀胱灌注力尔凡预防浅表性膀胱癌术后复发的疗效观察[J].中国肿瘤临床与康复,2012,19(3):278-279.
[14]沈建强,杨荣华.吡柔比星与羟喜树碱预防浅表性膀胱癌术后复发的疗效比较[J].中国现代医生,2012,50(14):146-147,150.
[15]靳锐.吡柔比星即刻灌注与术后一周灌注预防非肌层浸润性膀胱癌术后复发疗效对比[D].青海大学,2016.
[16]沈汉章.中西医结合治疗预防非肌层浸润性膀胱癌术后复发的临床研究[D].南京中医药大学,2016.
[17]李美凤,周小庆,曾菁.羟基喜树碱与表柔比星膀胱内灌注化疗预防膀胱癌术后复发的临床研究[J].中国临床药理学杂志,2015,33(15):1503-1505.
[18]桑子江.表浅性膀胱癌术后灌注EPI和THP预防复发的疗效比较[D].青海大学,2015.
[19]王鹏.FISH技术用于监测膀胱癌经尿道电切术后近期复发的价值研究[D].长江大学,2015.
[20]李嘉,陈国俊.表浅性膀胱癌术后膀胱灌注卡介苗随机对照试验的Meta分析[J].中国肿瘤生物治疗杂志,2011,18(1):70-74.
[2]林豪胜,吴保忠,杨帝宽.吡柔比星与丝裂霉素C膀胱内灌注预防浅表性膀胱癌术后复发的疗效比较[J].中国实用医药,2013,27(16):59-60.
[3]杨家荣,刘伟,刘波.膀胱癌患者尿液中BLCA-4表达的临床意义[J].实用癌症杂志,2015,30(2):168-170.
[4]Donaldson SB,Bonington SC,Kershaw LE,et al.Kershaw.Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect[J].Eur J Radiol,2013,82(12):634-638.
[5]罗建斌.经尿道膀胱肿瘤电切术联合化疗治疗T2a及T2b期膀胱癌的临床观察[J].实用癌症杂志,2015,4(9):1317-1319.
[6]王文俊,宣强.经尿道电切术和开放手术治疗早期膀胱癌的手术效果及预后比较[J].实用癌症杂志,2015,30(2):276-278.
[7]Zhang N,Jiang G,Liu X,et al.Prediction of bacillus calmette-guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies[J].Biomed Res Int,2016,2(6):634-638.
[8]Han E,Jang SY,Kim G,et al.Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes[J].Medicine,2016,95(6):634-638.
[9]Carina Bernardo,Céu Costa,Carlos Palmeira.What we have learned from urinary bladder cancer models[J].Journal of Cancer Metastasis and Treatment,2016,2(2):59.
[10]Di Mattina AJ,Fazelat A,Santaro A.Exudative retinal detachment reveals metastatic bladder cancer[J].Optom Vis Sci,2016,93(5):549-554.
[11]许丹,张丽东,徐彤,等.膀胱癌术后吡柔比星膀胱内灌注治疗的方法与护理对策[J].中国医药指南,2016,14(27):233-234.
[12]谢剑云,张新安,陈伟东.参斛汤联合吡柔比星膀胱灌注对膀胱癌术后患者不良反应、生存质量的影响[J].河南中医,2015,35(12):3042-3044.
[13]曹广辉,张治国,邱功阔.膀胱灌注力尔凡预防浅表性膀胱癌术后复发的疗效观察[J].中国肿瘤临床与康复,2012,19(3):278-279.
[14]沈建强,杨荣华.吡柔比星与羟喜树碱预防浅表性膀胱癌术后复发的疗效比较[J].中国现代医生,2012,50(14):146-147,150.
[15]靳锐.吡柔比星即刻灌注与术后一周灌注预防非肌层浸润性膀胱癌术后复发疗效对比[D].青海大学,2016.
[16]沈汉章.中西医结合治疗预防非肌层浸润性膀胱癌术后复发的临床研究[D].南京中医药大学,2016.
[17]李美凤,周小庆,曾菁.羟基喜树碱与表柔比星膀胱内灌注化疗预防膀胱癌术后复发的临床研究[J].中国临床药理学杂志,2015,33(15):1503-1505.
[18]桑子江.表浅性膀胱癌术后灌注EPI和THP预防复发的疗效比较[D].青海大学,2015.
[19]王鹏.FISH技术用于监测膀胱癌经尿道电切术后近期复发的价值研究[D].长江大学,2015.
[20]李嘉,陈国俊.表浅性膀胱癌术后膀胱灌注卡介苗随机对照试验的Meta分析[J].中国肿瘤生物治疗杂志,2011,18(1):70-74.